Rafael Holdings Q2 fiscal 2024 net income $5.9M; Day Three Labs stake raised to 79%

Rafael Holdings, Inc.

2024-Q2 EPS reported $0.10 revenue$136,000

Net income from continuing ops $5.9M ($0.25 diluted EPS) vs loss of $3.3M (-$0.13) YoY.
Cash and marketable securities $71.7M at Jan 31, 2024.
Investment in Cyclo Therapeutics contributed $9.7M unrealized gain; Day Three Labs loss $1.6M.
Increased ownership in Day Three Labs to 79% majority interest; consolidating results.
Appointed Dr. John Goldberg as Chief Medical Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rafael Holdings, Inc. reported second quarter of fiscal 2024 results: net income net income from continuing operations of $5.9 million, EPS $0.25 per fully diluted share.

Period: second quarter of fiscal 2024
Net income: net income from continuing operations of $5.9 million
EPS: $0.25 per fully diluted share
Result: reported results

Exact text from the filing

For the three months ended January 31, 2024, we recorded net income from continuing operations of $5.9 million, or $0.25 per fully diluted share

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Rafael Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-022271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.